Compare Cardinal Health Inc (CAH) vs Mattel Inc (MAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs Mattel Inc — how do they compare? Cardinal Health Inc trades at $228.59 (market cap $53.89B), while Mattel Inc trades at $13.72 (market cap $3.97B). The key difference: Cardinal Health Inc is far larger — about 13.6× Mattel Inc's market cap, and Cardinal Health Inc pays a 0.89% dividend while Mattel Inc pays none. Which is the better fit depends on your goals.
| CAH | MAT | |
|---|---|---|
Market Cap | $53.89B | $3.97B |
Sector | Health | Consumer Cyclical |
52-Week High | $239.71 | $22.16 |
52-Week Low | $146.04 | $13.05 |
Enterprise Value | $58.87B | $5.78B |
Dividend Yield | 0.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $233.66, down 0.91% in the last session, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.17 surpassing expectations. Revenue reached $222.58 billion in 2025, though net margins remain thin at 0.62%. Recent news highlights growth potential in medical supplies, with earnings results for fiscal 2026 due August 11.
The outlook for CAH is positive, driven by earnings momentum and sector tailwinds, but risks include high leverage with debt-to-asset ratio at 16.09% and competitive pressures. Analyst consensus is bullish with a $248 price target, suggesting 6% upside. Investors should weigh solid operational cash flow against negative shareholder equity and investing outflows.
Mattel (MAT) trades at $13.84, up 3.83% today, with a bullish technical signal and strong valuation metrics including a P/E of 8.86 and P/S of 0.81. Recent earnings showed a Q1 2026 beat but Q3-Q4 2025 misses, while revenue stability around $5.4B supports a 9.27% net margin. News highlights include Comic-Con exclusives and a Barbie-Dunkin' collaboration, though cash flow turned negative in 2025.
The stock presents value with low multiples and 50% analyst buy ratings, targeting $14.60 consensus. Risks include volatile earnings, debt load, and activist pressure for a sale. Upside depends on brand execution offsetting consumer spending sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →
